Sign In
Buy RYTM
$84.71
+0.360 (+0.427%)
At Close: Jun 03, 2026
Rhythm Pharma: An Incremental Approach Works Well For Setmelanotide
01:53pm, Wednesday, 28'th Dec 2022
Rhythm Pharmaceuticals is planning to get approvals for setmelanotide in an incremental fashion. Each new approval in a rare disease will add to the topline.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09:01pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families l
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript
03:56pm, Tuesday, 08'th Nov 2022
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Mee
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
01:25pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
12:05pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE N
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
09:48am, Tuesday, 08'th Nov 2022
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
11:30am, Wednesday, 02'nd Nov 2022 GlobeNewswire Inc.
-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent (16 of 18) patients achieved primary endpoint with a BMI decrease greater than 5 percent
Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
02:02pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
11:17am, Tuesday, 25'th Oct 2022
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
09:21pm, Monday, 24'th Oct 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
12:00pm, Friday, 23'rd Sep 2022 GlobeNewswire Inc.
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International --
Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
08:01pm, Monday, 19'th Sep 2022 GlobeNewswire Inc.
BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
08:38am, Friday, 16'th Sep 2022 Benzinga
Gainers
HeartBeam, Inc. (NASDAQ: BEAT) shares jumped 85.6% to close at $2.32 on Thursday after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
05:03pm, Thursday, 15'th Sep 2022 Benzinga
Gainers
HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrom
